Stallergenes Greer Submits a Marketing Authorisation Application in Europe for Its Sublingual House Dust Mite Allergen Immunotherapy Tablet
Stallergenes Greer, a biopharmaceutical company specialising in treatments for respiratory allergies, announces the submission of a marketing authorisation application for STAGR320, its sublingual house dust mite (HDM) immunotherapy (SLIT) tablet, via a European decentralized procedure.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200504005266/en/
“By further developing its portfolio of allergen immunotherapy solutions, Stallergenes Greer enables physicians and patients to determine the treatment alternative that best meets the clinical and immunological profile and the lifestyle needs of each individual. This significant milestone demonstrates our determination to offer patients and the medical community an extensive portfolio of personalised treatment options including injectable and sublingual therapies such as drops and tablets,” stated Michele Antonelli, CEO of Stallergenes Greer.
The STAGR320 phase III clinical trial, which included 1,600 patients from 231 participating investigative sites in 13 countries, assessed the treatment of HDM-induced allergic rhinitis in adult and adolescent patients. The trial achieved both its primary efficacy endpoint and key secondary endpoints and showed a comparable safety profile to that observed in other clinical studies with STAGR320. The randomized, double-blind, placebo-controlled trial was the largest phase III clinical trial conducted to evaluate the treatment of house dust mite allergy.
Allergic rhinitis affects more than 500 million people worldwide, who are at higher risk of developing rhinitis exacerbation and asthma than the general population. Allergic rhinitis can include symptoms such as sneezing, a runny or itchy nose, nasal congestion and watery or itchy eyes, among others1,2. Symptoms may be severe and can worsen over time and have a significant impact on quality of life1-3,4-5.
ABOUT STAGR320
STAGR320 is Stallergenes Greer’s investigational sublingual allergen immunotherapy (AIT) tablet for the treatment of HDM-induced allergic rhinitis, with or without intermittent asthma. Allergen immunotherapy uniquely alters the natural course of respiratory allergies. It is the only therapeutic class capable of modifying disease progression and potentially preventing the onset of the disease by inducing tolerance in the immune system. STAGR320 is registered under the brand name Actair® in Australia, Japan, New Zealand and South Korea for the treatment of HDM-induced allergic rhinitis in adults and adolescents. The indication is extended in Japan for use in children below 12 years of age.
The review by Health Canada of the New Drug Submission for STAGR320 is underway.
Stallergenes Greer’s STAGR320 HDM sublingual immunotherapy tablet strengthens the company’s tablet portfolio, which already includes Oralair® for the treatment of grass pollen allergies. STAGR320 contains the same active ingredient as the company’s Staloral® HDM sublingual solution formulation. Stallergenes Greer’s wide range of treatment options provides physicians with solutions tailored to the needs of each patient: sublingual tablet formulation for ease of use and convenience, and sublingual solution for flexible dosing according to each individual profile.
ABOUT STALLERGENES GREER Ltd
Headquartered in London (UK), Stallergenes Greer Ltd is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer Ltd is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France).
Additional information is available at https://www.stallergenesgreer.com/
REFERENCES
1. Bousquet J, Khaltaev N, Cruz A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008 Apr;63 Suppl 86:8-160.
2. Brożek JL, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) Guidelines – 2016 Revision, Journal of Allergy and Clinical Immunology (2017), doi: 10.1016/j.jaci.2017.03.050.
3. Linneberg A., Henrik Nielsen N., Frolund L, et al. The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study. Allergy. 2002 Nov;57(11):1048-1052.
4. Shin J-W, Sue J-H, Song T-W, et al. Atopy and house dust mite sensitization as risk factors for asthma in children. Yonsei Med J.2005;46: 629-634.
5. Hankin C. S., Cox L., Lang D.,et al. Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: a large-scale, retrospective, matched cohort study. Ann Allergy Asthma Immunol. 2010 Jan;104(1):79-85.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200504005266/en/
Contact information
Communications
Catherine Kress
Tel: +33 01 55 59 26 05
Email: catherine.kress@stallergenesgreer.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NetApp Transforms Enterprise Cloud with Google Cloud14.10.2025 15:00:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced that it has deepened its collaboration with Google Cloud to help customers accelerate cloud transformation and address critical business challenges. New block storage capabilities in Google Cloud NetApp Volumes enhance unified storage for today’s most important data workloads, including virtualized environments, self-managed databases, and AI innovation. The NetApp data platform enables any Al model—whether on-premises or in any major public cloud—to securely access a customer’s entire data estate, without needing to move data between environments. New integrated caching capabilities in Google Cloud NetApp Volumes allow for seamless access to that unified data foundation, along with advanced new integrations with Gemini Enterprise, empowering customers to break down silos, eliminate complexity, and accelerate their AI journeys. “With the enhancements to Google Cloud NetApp Volumes, including the additi
NetApp Collaborates with Cisco on Enterprise-Grade Converged Infrastructure with Disaggregated Storage for AI14.10.2025 15:00:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced a collaboration with Cisco to deliver a significant evolution in converged infrastructure that builds on over 20 years of work together. The newly introduced NetApp AFX architecture now integrates with Cisco Nexus switches for intra-cluster connectivity and will soon extend to FlexPod AI. This integration continues the companies’ shared vision of providing customers with an enterprise-grade foundation for AI. NetApp AFX is powered by a disaggregated NetApp ONTAP, the industry-leading storage operating system trusted by tens of thousands of enterprise customers across industries to manage exabytes of data. The integration of Cisco Nexus 400G switches delivers the ultra-high bandwidth, low-latency, and lossless networking essential for scaling AI workloads. This ensures that customers can meet the performance demands of modern AI networks while maintaining enterprise-grade reliability and simplicity. “Th
NetApp Introduces Comprehensive Enterprise-Grade Data Platform for AI14.10.2025 15:00:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today unveiled visionary new products, strengthening its enterprise-grade data platform for AI innovation. As the era of AI shifts from initial pilots to mission-critical agentic applications, AI-ready data on modern enterprise-grade data infrastructure delivers the results needed for AI-driven businesses. The new NetApp AFX decouples performance and capacity with a disaggregated NetApp ONTAP that runs on the new NetApp AFX 1K storage system. NetApp AI Data Engine is a secure, unified extension of ONTAP integrated with the NVIDIA AI Data Platform reference design that helps organizations simplify and secure the entire AI data pipeline – and managed via single, unified control plane. Together, these capabilities unify high-performance storage and intelligent data services into a single, secure, and scalable offering that accelerates enterprise AI retrieval augmented generation (RAG) and inference across hybrid and mult
NetApp First to Embed Data Breach Detection into Enterprise Data Storage14.10.2025 15:00:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced new industry-leading cyber resilience capabilities that further strengthen the most secure storage on the planet. The newly enhanced and renamed NetApp Ransomware Resilience service enables customers to make their data infrastructure a leading part of their comprehensive security strategy with integrated AI-powered ransomware detection and two new capabilities: a first-in-the-industry ability for enterprise storage to detect data breaches; and isolated recovery environments to enable safe and clean recovery of mission-critical data. As enterprises face their most pressing challenges—AI innovation, data modernization, cyber resilience, and cloud transformation—they need a secure, reliable, and efficient data infrastructure. While investments in AI are creating unprecedented opportunity for enterprises, they are also expanding their attack surfaces. NetApp makes data infrastructure a critical part of ent
NetApp and Red Hat Strengthen Collaboration to Drive IT Modernization with Red Hat OpenShift Virtualization14.10.2025 15:00:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, and Red Hat, the world's leading provider of open-source solutions, today announced an expanded collaboration to deepen their joint development efforts and accelerate adoption of Red Hat OpenShift Virtualization across on-premises and public cloud environments. Through this enhanced collaboration, Red Hat and NetApp are helping customers more easily modernize their IT environments and navigate the complexities of migrating cloud-native workloads with greater confidence. A key aspect of Red Hat and NetApp’s collaboration is their mutual adoption of the other’s technologies in advancing each company’s operational and IT systems. NetApp is now running its development and testing engineering environments on Red Hat OpenShift Virtualization, the virtualization capability provided in all editions of Red Hat OpenShift, enabling faster provisioning, reduced complexity, and greater agility. By leveraging Red Hat OpenShift Virt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom